MGM Resorts International (MGM) Stock Price Today
Aura AI Summary
Key Stats
- $11.64BMarket Cap
- -Volume
- Consumer CyclicalSector
- $50.6952W High
- $30.7252W Low
- -Typical Hold Time
- $40.68BEnterprise Value
- 0.03%Div Yield
- -Trading Activity
Track MGM Resorts International (MGM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, MGM Resorts International has traded between a low of $30.72 and a high of $50.69, highlighting its annual price range. Buy and sell MGM Resorts International shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Most Recent News
Embedded LLM launches TokenVisor Spaces for governed AI agent services on AMD-powered clouds.
Embedded LLM has introduced TokenVisor Spaces, a new product that enables AI cloud operators and enterprises to run governed, auditable AI agent services on AMD-powered infrastructure. The solution combines AMD EPYC CPUs for agent execution and AMD I...

Bloom Energy set for major growth with AI demand and Oracle contract boosting Q2 earnings forecast.
Bloom Energy is poised for significant growth driven by rising AI demand and a major contract with Oracle, which may purchase up to 2.8 gigawatts of its fuel cells. RBC Capital maintains an "Outperform" rating, reflecting confidence in the company's ...

Over 80 companies develop 90+ molecular glues, advancing treatments for cancer and other diseases.
DelveInsight reports a competitive landscape with 80+ companies developing over 90 molecular glue therapies targeting diseases like cancer, immunology, and neurodegeneration. These small molecules promote protein degradation to treat previously 'undr...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.